- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03818100
Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible (Neo-RT)
Neo-RT: Pre-operative Breast Intensity Modulated Radiotherapy in Patients Receiving Neo-adjuvant Hormonal Treatment for Breast Cancer - a Feasibility Study.
Four in 10 women diagnosed with breast cancer undergo mastectomy with or without breast reconstruction and less than half are satisfied with how they look unclothed. Breast conservation (removing the area with the lump only) can offer less extensive surgery and improved breast appearance, which can therefore increase well-being.
Intensity-modulated radiotherapy (IMRT) closely shapes the radiation beam to the cancer and is currently given after breast surgery. A new combination of IMRT followed by hormone treatment given before surgery, may increase the possibility of breast conservation.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Victoria Ingleson, BSc
- Phone Number: 01223 349702
- Email: victoria.ingleson@addenbrookes.nhs.uk
Study Contact Backup
- Name: Anne-Laure Vallier
- Phone Number: 01223 348086
- Email: anne-laure.vallier@addenbrookes.nhs.uk
Study Locations
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
- Recruiting
- Cambridge University Hospitals NHS Foundation Trust
-
Contact:
- Anne-Laure Vallier
- Phone Number: 01223 348086
- Email: anne-laure.vallier@addenbrookes.nhs.uk
-
Contact:
- Meena Murthy, BSc
- Phone Number: 01223 349702
- Email: meena.murthy@addenbrookes.nhs.uk
-
Principal Investigator:
- Charlotte Coles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent to participate
- Female
- Aged 18 years and older
- ECOG performance status 0-2
- Histology confirmed invasive breast cancer
- ER positive (Allred score 6-8)
- HER2 negative
- Palpable size ≥20mm
- Grade I-II (or grade III if considered not suitable for neo-adjuvant chemotherapy)
- Considered that radiotherapy will make breast conserving surgery easier
- No evidence of non-breast malignancy if treated with curative intent unless the patient has been disease free ≥5 years
- Unifocal or multifocal disease, i.e. tumour in the same quadrant and breast conserving surgery still feasible
Exclusion Criteria:
- Contraindications to breast radiotherapy or neo-adjuvant endocrine therapy
- Bilateral breast cancer
- Metastatic cancer
- Multicentric disease
- Concomitant medical/psychiatric problems preventing completion of study treatment or follow-up
- Pregnancy
- Breast feeding
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients successfully completing neo-adjuvant IMRT and endocrine treatment followed by beast surgery, as per study protocol.
Time Frame: 6 months
|
Successful completion of IMRT is defined as:
Successful completion of endocrine treatment is defined as:
Successful surgery is defined as:
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute radiotherapy toxicity following IMRT, assessed by CTCAE v4.03
Time Frame: 3 weeks
|
Acute radiotherapy toxicity following IMRT, assessed by CTCAE v4.03
|
3 weeks
|
Mastectomy rate
Time Frame: 6 months
|
Analysis will be descriptive, and in accordance to the statistical analysis plan.
|
6 months
|
Peri/post operative complications
Time Frame: 9 months
|
Including:
|
9 months
|
Volume of residual tumour and response to treatment
Time Frame: 6 months
|
There will be a central review (2 readers) of all primary surgery histopathology reports for the secondary endpoint of pathological complete response (pCR).
The histopathology slides from the surgical resection will be requested for central assessment of residual disease for all cases where there has not been a pCR.
The variables that will be recorded include residual invasive tumour size in two dimensions, residual invasive tumour cellularity, number of lymph node metastases and size of the largest metastasis.
A representative tumour tissue block will be selected and requested from the laboratory.
Sections from the block will be taken for staining with ER and Ki67 to allow calculation of the histological assessment of residual tumour burden, and cores taken as per the protocol.
|
6 months
|
Late normal tissue toxicity, as assessed by: 1) clinicians
Time Frame: Annually for 5 years
|
Clinician - post-radiotherapy questionnaire (with permission from IMPORT Trial Management Group and Dr Penny Hopwood)
|
Annually for 5 years
|
Late normal tissue toxicity, as assessed by: 2) Patient Reported Outcome Measurements (PROMs)
Time Frame: Annually for 5 years
|
Patient Reported Outcome Measure - Validated Breast-Q questionnaire
|
Annually for 5 years
|
Late normal tissue toxicity, as assessed by: 2) Patient Reported Outcome Measurements (PROMs)
Time Frame: Annually for 5 years
|
Patient Reported Outcome Measure - EORTC IL1 Modified BRECON23 PROM questionnaire.
|
Annually for 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory research will be carried out to identify possible molecular and radiological biomarkers of response
Time Frame: 6 months post last patient recruited
|
Exploratory investigation of potential biomarkers include:
Immune response (TILs) Tumour proliferation (Ki67, Geminin) DNA damage response and cell cycle checkpoint activation (including 53BP1, RAD51, ATM1, BRCA1, p53, p21 and p-chk-1) Tumour microenvironment (hypoxia) - Multiplexed single cell proteomics of both cellular suspensions (including whole blood) and intact tissues, to investigate the immune response and other novel markers Since the identification of new biomarkers correlating with disease activity and the efficacy or safety of treatment is rapidly evolving, the definitive list of biomarkers remains to be determined. However they will be detailed in an appropriate analysis plan prior to undertaking any sample analysis. |
6 months post last patient recruited
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charlotte E Coles, MB ChB, MRCP, FRCR, PhD, University of Cambridge
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neo-RT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on Intensity modulated radiotherapy (IMRT)
-
New Mexico Cancer Care AllianceCompletedNeoplasm Metastasis | Central Nervous System MetastasesUnited States
-
University College, LondonCancer Research UK; NCRI Radiotherapy Trials QA (RTTQA) GroupCompletedEwing Sarcoma | Chordoma | Bone Sarcoma | Soft Tissue Sarcoma, AdultUnited Kingdom, Ireland
-
M.D. Anderson Cancer CenterUnknownProstate CancerUnited States
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Institut Claudius RegaudWithdrawn
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
The Central Hospital of Lishui CityNot yet recruitingEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedNeoplasm MetastasisUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingMelanoma | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Esthesioneuroblastoma | Squamous Cell Carcinoma | Sinonasal Carcinoma | Myoepithelial Carcinoma | Sinonasal Undifferentiated Carcinoma | Schneiderian CarcinomaUnited States
-
Jun-Lin Yi, MDRecruiting